Purpose {#S0001}
=======

3D image-based treatment planning for gynaecological (GYN) cancer is a recent innovation \[[@CIT0001]--[@CIT0007]\] where magnetic resonance imaging (MRI) and computerized tomography (CT) are used to accurately define target volumes, organs at risk (OARs), and applicator position \[[@CIT0005]\]. Dose calculations are dependent on the geometrical accuracy of the source position relative to target volumes and OARs \[[@CIT0008]\]. The challenge with 3D image guidance in most centers is that the patient must be transferred out of the high-dose-rate (HDR) brachytherapy (BT) operating room for imaging. The patient transfer between applicator implantation, imaging, and radiation delivery can cause applicator displacements. These applicator displacements lead to dosimetric errors to the target volume and OARs \[[@CIT0004], [@CIT0008]\]. Gerzten *et al*. have researched applicator shifts due to patient movement from simulation to HDR treatment rooms \[[@CIT0009]\]. However, applicator displacements were evaluated on orthogonal radiographs, and no dosimetric impact on target volumes and OARs were measured. Real time applicator monitoring systems using Microsoft\'s KINECT™ system (Microsoft Corp. Redmond, WA, USA) was recently introduced as a possible solution to monitor intracavitary applicator displacement with less than or equal to 1 mm resolution for applicator displacement during additional 3D scans in a different room \[[@CIT0010]\]. However, to set applicator displacement limits, it is important to first understand its dosimetric impact. No study has yet presented the dosimetric impact of intracavitary applicator displacements for both conventional, point A plans and 3D image-guided, conformal plans.

Another major challenge facing 3D image guided planning is to reconstruct the source-pathway on the 3D image, especially those on MRI. Exclusive MRI-based applicator reconstruction methodologies were introduced for different applicators for cervical cancer such as plastic tandem-and-ovoids (T&O) \[[@CIT0011], [@CIT0012]\], plastic tandem-and-ring (T&R) applicators \[[@CIT0013]\], titanium T&R applicators \[[@CIT0013]\], titanium Rotterdam applicators \[[@CIT0014]\], and Vienna applicators (plastic T&R plus supplementary needles) \[[@CIT0003]\]. Among the first applicator reconstruction accuracy studies \[[@CIT0004], [@CIT0006], [@CIT0011]--[@CIT0015]\] on MRI, two reports \[[@CIT0007], [@CIT0014]\] presented absolute reconstruction uncertainties using phantom studies for plastic and titanium T&R \[[@CIT0007]\] and titanium Rotterdam applicators \[[@CIT0014]\], while other reports presented relative comparison data using different reconstruction methods \[[@CIT0015]\] or different MRI scanning protocols \[[@CIT0012]\]. When a plastic applicator is used for MRI guided BT, the signals of the MRI-marker catheters \[[@CIT0011]\] are able to guide clinicians to reconstruct applicator position based on their hyposignals. The use of titanium applicators using MRI makes their reconstruction much more difficult due to the artifacts they create. Recently a novel Marker-Flange \[[@CIT0016]\] was introduced to improve the reconstruction accuracy of titanium applicators when used with applicator library. GEC-ESTRO (Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology) reported the considerations and pitfalls in new applicator commissioning, and the reconstruction uncertainties this entailed with a 3D image \[[@CIT0004]\]. However, 3D imaging reconstruction uncertainties should always be validated in each clinic when a clinic implements a 3D image guided BT program, since reconstruction uncertainties are associated with each institutional scanning protocols, the type of CT or MRI scanner, the type of applicator, applicator material, treatment planning system (TPS), and planning workflow. For instance, when a titanium applicator is used with a CT scanner, the titanium applicator on the CT image can have a bigger diameter (e.g. 6 mm versus 3.2 mm) due to the Hounsfield unit changes between the titanium and adjacent tissue. Namely, when a default-window level is used, if a clinician defines the end of bright white signal on CT as a tip of tandem, this can cause systematic reconstruction errors that result in systematic dosimetric errors. It is important to understand the estimated dosimetric impact of the reconstruction uncertainties. For MRI-guided, conformal BT plans, Tanderup *et al*. \[[@CIT0008]\] presented the dosimetric impact of T&R on target volumes and OARs through by virtually shifting or rotating each tandem and ring before performing dose calculations of volume optimization. No study has yet presented the dosimetric impact of reconstruction accuracy for conventional, point A plans. In this study, we present the dosimetric impact of applicator displacement and applicator reconstruction-uncertainties on target volumes and OARs for both conventional, point-A plans, and 3D image guided conformal plans.

Material and methods {#S0002}
====================

HDR brachytherapy planning: point A and MRIG-CBT plans {#S20003}
------------------------------------------------------

Conventional point A plans were clinically generated on for MRI, following the recommendations of the American Brachytherapy Society consensus guidelines \[[@CIT0017], [@CIT0018]\]. The BrachyVision™ (Varian Medical Systems Inc., Palo Alto, CA, USA) TPS was used. A high resolution (3.0 Tesla) Siemens MAGNETOM Trio 3T MR scanner (Siemens Medical Solutions Inc., Erlangen, Germany) was used for all MR scanning following the same GYN MRI protocols as previously reported \[[@CIT0019]\]. Twenty randomly selected HDR cases were retrospectively studied after Institutional Review Board approval was secured. A titanium Fletcher-Suit-Delclos T&O applicator (Varian Medical Systems, Inc.) was used for all implants, along with gauze packing. The position of the bladder foley at the most inferior bladder neck was checked after foley insertion, and also re-checked on MRI. Orthogonal radiographs using a C-arm were taken before and after each MRI scan (Pre- and Post-X-ray). The institutional protocols for external beam radiotherapy and HDR BT fractionation schemes were detailed in previous studies \[[@CIT0007], [@CIT0020]--[@CIT0022]\]. High-risk clinical target volumes (HR-CTV), of the rectum, bladder, and sigmoid were retrospectively delineated as per GEC-ESTRO recommendations \[[@CIT0002], [@CIT0003]\]. For each point A plan, a MRI-guided, conformal BT (MRIG-CBT) plan was retrospectively generated using the hybrid-inverse optimization detailed in a previous study \[[@CIT0007]\].

Simulating T&O displacements and T&O reconstruction-uncertainties {#S20004}
-----------------------------------------------------------------

To simulate T&O displacements, in unshifted, original point A plans ([Figs. 1B](#F0001){ref-type="fig"}, [D](#F0001){ref-type="fig"}) and MRIG-CBT ([Figs. 1C](#F0001){ref-type="fig"}, [E](#F0001){ref-type="fig"}), a whole T&O ([Fig. 1A](#F0001){ref-type="fig"}) was virtually shifted in a cranial (+) or caudal (--) direction in ± 1.5, ± 3, ± 5, ± 6, ± 7.5, ± 10, and ± 20 mm increments after dose calculations ([Fig. 1](#F0001){ref-type="fig"}). Simply put, the whole T&O was shifted cranio-caudally while dwell times and positions were kept unchanged (the unshifted plan) in order to model the physical T&O displacement that can occur during patient transfer between the BT treatment room and CT or MRI scanning room. Given that, the T&O is tightly packed with gauze and tandem angle limits torque, the T&O rarely rotates, but is often displaced in a cranial-caudal direction during 3D scanning. For the purpose of this study, only the T&O displacement in cranial-caudal direction was simulated in this study. Absolute dosimetric changes due to virtual shifting were measured for both point-A and MRIG-CBT plans between an unshifted and a shifted plan.

![The simulated T&O displacements on a treatment planning system by virtual shifting whole T&O (A). The original unshifted plans of conventional, point A technique (B) and MRIG-CBT (C). The resulting isodose lines due to --20 mm shift for conventional plan (D) and MRIG-CBT plan (E)](JCB-5-21922-g001){#F0001}

Regarding T&O reconstruction-uncertainty simulations, a tandem and two ovoids were shifted along their central axis (see [Fig. 2A](#F0002){ref-type="fig"}), since reconstruction uncertainties exist mainly along their central axis when an applicator library is used. Unlike that the ring reconstruction uncertainties for T&R that occur when it rotates, ovoid reconstruction uncertainties for T&O occur in a posterior-anterior direction along the central axis of the ovoid-tandem ([Fig. 2A](#F0002){ref-type="fig"}). We defined (+) direction and (--) direction for either tandem or ovoid motion when a source-wire travels longer (shorter), along its source-pathway. As a result, a tandem was virtually shifted in a cranial (+) or caudal (--) direction, while each ovoid was virtually shifted in a posterior (+) or anterior (--) direction. For the purpose of this study, a tandem and both ovoids were virtually shifted in increments of ± 1.5, ± 3.0, ± 4.5, ± 6.0, ± 7.5, and ± 10 mm. For instance, a --10 mm shifted plan represents a tandem is shifted 10 mm in a caudal direction and each ovoid is shifted 10 mm in an anterior direction as depicted in [Fig. 2A](#F0002){ref-type="fig"}. After virtual shifting was completed, dose calculations of either a point A plan or a MRIG-CBT plan was performed, given applicator reconstruction. For the point A plan ([Fig. 2B](#F0002){ref-type="fig"}), reference optimization lines were created based upon the shifted applicator and optimization was done using those regenerated reference lines. For the MRIG-CBT plan ([Fig. 2C](#F0002){ref-type="fig"}), a hybrid-inverse optimization \[[@CIT0007], [@CIT0023]\] was performed after each shift. It is noted that the isodose lines (i.e. dwell times) are delivered at the correct dwell positions, even when an applicator is reconstructed inaccurately (i.e. a shift of a couple of mm from the true position). To simulate delivered-isodose lines, we shifted the calculated isodose lines and the T&O back to its original position ([Figs. 2D](#F0002){ref-type="fig"},[E](#F0002){ref-type="fig"}) which we then used as a reference plan. Each shifted plan has its own reference plan. Afterward, we compared the dose parameters between the shifted plans ([Figs. 2B](#F0002){ref-type="fig"},[C](#F0002){ref-type="fig"}) and their reference plans ([Figs. 2D](#F0002){ref-type="fig"},[E](#F0002){ref-type="fig"}).

![The simulated T&O reconstruction uncertainties on a treatment planning system by shifting each tandem and ovoid (A). The resulting isodose lines of conventional plan (B) and MRIG-CBT plan (C) after --10 mm shift to simulate T&O reconstruction uncertainties and dose calculation. To evaluate their dosimetric impacts, the plans of B and C were compared to their simulated, delivered plans (D and E, respectively) that were created by shifting T&O back to their original position and dose calculation](JCB-5-21922-g002){#F0002}

Dosimetric changes on dose-volume parameters of the HR-CTV (D~100~ and D~90~), the rectum (D~2cc~), the bladder (D~2cc~), and the sigmoid (D~2cc~) were recorded for both point A and MRIG-CBT plans. In addition, dosimetric changes of point A (left and right points) and ICRU report \#38 defined, rectal and bladder points were quantified. To normalize the prescription dose differences, the percent dose differences were calculated for all dosimetric metrics. The *p*-values were calculated using a two-tailed *t*-test.

Results {#S0005}
=======

Dosimetric impact of T&O displacements {#S20006}
--------------------------------------

The dosimetric impact of simulated T&O displacements on sigmoid (*p* \< 0.0005), bladder (*p* \< 0.0001), HR-CTV (*p* \< 0.0036), and point A (*p* \< 0.0015) were significantly larger for the MRIG-CBT plans than the point A plans. MRIG-CBT plans data in [Table 1](#T0001){ref-type="table"} clearly presented more dark (dosimetric changes ≥ 15%) and gray (dosimetric changes ≥ 10%) regions than point A plans as seen in [Table 2](#T0002){ref-type="table"}. Rectal D~2cc~ values were observed as the most sensitive to change due to the T&O displacement across all dosimetric metrics, regardless of point A (*p* \< 0.013) or MRIG-CBT plans (*p* \< 0.0277). Even a 3 mm T&O displacement caused an average 10-12% dosimetric change on rectal D~2cc~ for both point A plans ([Table 2](#T0002){ref-type="table"}) and MRIG-CBT plans ([Table 1](#T0001){ref-type="table"}). A 5 mm T&O displacement resulted in clinically unacceptable dosimetric changes on rectal D~2cc~ for point A plans (average 17-21%, [Table 2](#T0002){ref-type="table"}) and MRIG-CBT plans (average 16-22%, [Table 1](#T0001){ref-type="table"}). A 1.5 mm T&O displacement solely presented less than a 10% dosimetric change (average 6%) for both point A ([Table 2](#T0002){ref-type="table"}) and MRIG-CBT plans ([Table 1](#T0001){ref-type="table"}). The D~2cc~ value for rectum showed a larger dosimetric change than the ICRU rectal point doses for point A (*p* \< 0.0389) and MRIG-CBT plans (*p* \< 0.0699). A more than 5 mm T&O displacement in a cranial direction resulted in a greater than 10% change in bladder D~2cc~ for MRIG-CBT plans. Bladder (D~2cc~) of point A plans presented a relatively low dosimetric change (less than 10%) up to 7.5 mm T&O displacement. Sigmoid (D~2cc~) also had a relatively low dosimetric change (less than 10%) up to 10 mm and 7.5 mm T&O displacement for both point A and MRIG-CBT plans, respectively. HR-CTV (D~100~ and D~90~) was also found to change less than 10% for up to 10 mm (7.5 mm) of the T&O displacement for MRIG-CBT plans (point A plans). The point A doses were found to be less than 10% of the changes for up to 10 mm in the T&O displacement for point A plans, since point A locates on the reference optimization lines. However, more changes in the point A doses were observed (11-17% changes per 10 mm displacement) in MRIG-CBT plans, since they don\'t have typical pear-shape isodose lines, but have conformal isodose lines.

###### 

The simulated dosimetric impacts of T&O displacements for MRIG-CBT (20 plans) by virtually shifting whole T&O in a treatment planning system

                         Simulated dosimetric impacts \[%\] of T&O displacements for MRIG-CBT plans                                                                                                                  
  ---------------------- ---------------------------------------------------------------------------- --------- --------- --------- --------- -------- ------- ------- -------- -------- -------- -------- --------- ---------
  HR-CTV D~90~ \[%\]     23 ± 11                                                                      9 ± 5     7 ± 4     9 ± 3     5 ± 3     3 ± 2    2 ± 1   1 ± 1   3 ± 2    5 ± 4    7 ± 5    8 ± 6    11 ± 8    21 ± 16
  HR-CTV D~100~ \[%\]    20 ± 9                                                                       6 ± 9     7 ± 5     6 ± 4     5 ± 4     3 ± 3    2 ± 2   2 ± 1   4 ± 2    6 ± 3    7 ± 4    9 ± 5    11 ± 7    24 ± 11
  Rectum D~2cc~ \[%\]    136 ± 46                                                                     50 ± 13   35 ± 8    27 ± 6    22 ± 5    12 ± 3   6 ± 1   6 ± 1   10 ± 2   16 ± 4   19 ± 4   23 ± 5   29 ± 6    47 ± 10
  Badder D~2cc~ \[%\]    29 ± 10                                                                      14 ± 7    11 ± 5    8 ± 5     7 ± 4     4 ± 3    2 ± 1   2 ± 2   5 ± 3    8 ± 6    10 ± 7   13 ± 9   19 ± 13   50 ± 42
  Sigmoid D~2cc~ \[%\]   24 ± 12                                                                      12 ± 6    8 ± 5     7 ± 4     5 ± 3     3 ± 2    2 ± 1   1 ± 1   3 ± 2    5 ± 3    5 ± 3    6 ± 4    9 ± 7     13 ± 9
  Point A left \[%\]     28 ± 14                                                                      12 ± 8    9 ± 6     7 ± 4     6 ± 4     4 ± 2    2 ± 1   2 ± 1   3 ± 2    5 ± 4    7 ± 4    8 ± 5    11 ± 8    41 ± 31
  Point A right \[%\]    28 ± 17                                                                      13 ± 9    10 ± 7    8 ± 5     7 ± 4.5   4 ± 3    2 ± 2   2 ± 2   4 ± 3    8 ± 5    9 ± 7    12 ± 9   17 ± 13   65 ± 53
  ICRU rectum \[%\]      60 ± 53                                                                      31 ± 23   23 ± 16   18 ± 12   15 ± 10   9 ± 6    4 ± 3   4 ± 2   8 ± 4    14 ± 6   16 ± 7   20 ± 8   26 ± 9    46 ± 11
  ICRU bladder \[%\]     27 ± 14                                                                      14 ± 9    11 ± 6    9 ± 5     7 ± 4     5 ± 3    2 ± 1   3 ± 1   5 ± 3    9 ± 5    10 ± 6   13 ± 8   18 ± 11   35 ± 26
                                                                                                                                                                                                                     
                         \< 5%                                                                        ≥ 5%      ≥ 10%     ≥ 15                                                                                       

T&O -- tandem-and-ovoids, HR-CTV -- high risk clinical target volume, D~90~ (D~100~) -- minimum dose covering 90% (100%) of the volume, D~2cc~ -- dose of the 2cc of the highest dose, ICRU rectum (bladder) -- ICRU report \#38 defined rectal (bladder) point

###### 

The simulated dosimetric impacts of T&O displacements for conventional planning (20 plans) by virtually shifting whole T&O in a treatment planning system

                         Simulated dosimetric impacts \[%\] of T&O displacements for conventional point A system                                                                                                               
  ---------------------- ----------------------------------------------------------------------------------------- --------- --------- -------- -------- -------- ------- ------- -------- -------- -------- -------- -------- ---------
  HR-CTV D~90~ \[%\]     9 ± 7                                                                                     5 ± 4     4 ± 4     3 ± 3    3 ± 2    2 ± 2    1 ± 1   1 ± 1   2 ± 2    3 ± 3    4 ± 3    5 ± 4    7 ± 5    18 ± 10
  HR-CTV D~100~ \[%\]    11 ± 9                                                                                    6 ± 4     5 ± 4     4 ± 3    3 ± 2    2 ± 2    1 ± 1   2 ± 2   3 ± 2    4 ± 3    5 ± 4    6 ± 5    8 ± 7    18 ± 10
  Rectum D~2cc~ \[%\]    138 ± 60                                                                                  52 ± 20   35 ± 12   27 ± 8   21 ± 6   12 ± 3   6 ± 1   6 ± 1   10 ± 3   17 ± 4   20 ± 5   24 ± 5   29 ± 6   47 ± 9
  Badder D~2cc~ \[%\]    13 ± 6                                                                                    6 ± 3     5 ± 2     4 ± 2    3 ± 2    2 ± 1    1 ± 1   1 ± 1   2 ± 1    4 ± 2    6 ± 3    8 ± 4    12 ± 5   41 ± 27
  Sigmoid D~2cc~ \[%\]   15 ± 10                                                                                   6 ± 5     5 ± 4     4 ± 3    3 ± 2    2 ± 1    1 ± 1   1 ± 1   2 ± 1    3 ± 2    3 ± 3    4 ± 3    5 ± 5    11 ± 8
  Point A left \[%\]     8 ± 8                                                                                     3 ± 2     3 ± 2     2 ± 1    2 ± 1    1 ± 1    0 ± 0   0 ± 1   1 ± 1    2 ± 2    2 ± 2    2 ± 3    4 ± 4    41 ± 26
  Point A right \[%\]    8 ± 8                                                                                     3 ± 3     2 ± 2     2 ± 2    2 ± 2    1 ± 1    1 ± 1   1 ± 1   1 ± 1    2 ± 2    3 ± 2    4 ± 3    6 ± 5    55 ± 61
  ICRU rectum \[%\]      47 ± 28                                                                                   25 ± 14   18 ± 10   14 ± 8   12 ± 6   7 ± 3    3 ± 2   4 ± 2   7 ± 3    11 ± 4   14 ± 5   17 ± 6   22 ± 7   42 ± 9
  ICRU bladder \[%\]     12 ± 7                                                                                    6 ± 4     5 ± 3     4 ± 2    3 ± 2    2 ± 1    1 ± 1   1 ± 1   2 ± 2    4 ± 3    5 ± 3    7 ± 5    10 ± 7   24 ± 17
                                                                                                                                                                                                                               
                         \< 5%                                                                                     ≥ 5%      ≥ 10%     ≥ 15                                                                                    

T&O -- tandem-and-ovoids, HR-CTV -- high risk clinical target volume, D~90~ (D~100~) -- minimum dose covering 90% (100%) of the volume, D~2cc~ -- dose of the 2cc of the highest dose, ICRU rectum (bladder) -- ICRU report \#38 defined rectal (bladder) point

Dosimetric impact of T&O reconstruction-uncertainties {#S20007}
-----------------------------------------------------

Our findings suggest that in order to avoid more than 10% dosimetric changes in any dosimetric parameter either point A ([Table 4](#T0004){ref-type="table"}) or MRIG-CBT plans ([Table 3](#T0003){ref-type="table"}), had to have less than or equal to ± 3.0 mm reconstruction-uncertainty. For conventional point A plans, the rectum (D~2cc~, ICRU point) and bladder (ICRU point) presented greater dosimetric changes due to the reconstruction uncertainties ([Table 4](#T0004){ref-type="table"}). The rectal D~2cc~ value recorded was the most sensitive to the T&O reconstruction. To ensure that less than 10% dosimetric change occurred in rectal D~2cc~ a value of less than or equal to ± 1.5 mm in reconstruction uncertainty was required. A 3 mm reconstruction uncertainty in the cranial direction caused an average 15% dosimetric change in rectal D~2cc~. ICRU bladder point presented a greater than 10% change due to the 4.5 mm T&O reconstruction uncertainty in the caudal direction. ICRU bladder point doses were observed to be more sensitive than bladder D~2cc~ due to the close proximity of the ovoids.

###### 

The simulated dosimetric impacts of T&O reconstruction-uncertainties for MRIG-CBT (20 plans)

                         Simulated dosimetric impact \[%\] of T&O reconstruction-uncertainties for MRIG-CBT plans                                                                                          
  ---------------------- ------------------------------------------------------------------------------------------ --------- --------- ------- ------- ------- ------- ------- -------- -------- -------- ---------
  HR-CTV D~90~ \[%\]     4 ± 4                                                                                      3 ± 4     3 ± 3     2 ± 3   2 ± 2   1 ± 1   1 ± 1   2 ± 2   3 ± 3    4 ± 5    5 ± 6    8 ± 8
  HR-CTV D~100~ \[%\]    8 ± 9                                                                                      7 ± 8     6 ± 6     4 ± 5   4 ± 3   2 ± 2   2 ± 2   3 ± 3   4 ± 4    5 ± 6    6 ± 6    10 ± 9
  Rectum D~2cc~ \[%\]    8 ± 7                                                                                      9 ± 8     9 ± 8     7 ± 6   5 ± 4   2 ± 2   1 ± 1   3 ± 2   5 ± 5    7 ± 5    8 ± 7    14 ± 14
  Badder D~2cc~ \[%\]    8 ± 11                                                                                     6 ± 9     5 ± 7     4 ± 5   3 ± 3   2 ± 2   2 ± 2   4 ± 3   6 ± 5    9 ± 6    11 ± 7   16 ± 11
  Sigmoid D~2cc~ \[%\]   5 ± 6                                                                                      4 ± 5     4 ± 4     3 ± 3   3 ± 3   2 ± 3   1 ± 2   3 ± 3   4 ± 6    6 ± 6    7 ± 7    11 ± 9
  Point A left \[%\]     4 ± 3                                                                                      3 ± 2     3 ± 2     2 ± 2   2 ± 1   1 ± 1   1 ± 1   2 ± 2   3 ± 2    4 ± 3    5 ± 4    8 ± 7
  Point A right \[%\]    4 ± 3                                                                                      3 ± 3     4 ± 3     3 ± 2   2 ± 2   2 ± 2   1 ± 2   3 ± 4   3 ± 4    4 ± 5    5 ± 4    7 ± 6
  ICRU rectum \[%\]      12 ± 9                                                                                     10 ± 9    8 ± 8     6 ± 7   4 ± 4   2 ± 2   2 ± 2   4 ± 4   6 ± 6    8 ± 7    10 ± 8   13 ± 11
  ICRU bladder \[%\]     15 ± 16                                                                                    12 ± 13   10 ± 10   8 ± 8   7 ± 5   4 ± 2   4 ± 2   7 ± 4   10 ± 6   13 ± 7   16 ± 9   21 ± 10
                                                                                                                                                                                                           
                         \< 5%                                                                                      ≥ 5%      ≥ 10%     ≥ 15                                                               

T&O -- tandem-and-ovoids, HR-CTV -- high risk clinical target volume, D~90~ (D~100~) -- minimum dose covering 90% (100%) of the volume, D~2cc~ -- dose of the 2cc of the highest dose, ICRU rectum (bladder) -- ICRU report \#38 defined rectal (bladder) point

###### 

The simulated dosimetric impacts of T&O reconstruction-uncertainties for conventional planning (20 plans)

                         Simulated dosimetric impact \[%\] of T&O reconstruction-uncertainties for conventional point A plans                                                                                                
  ---------------------- ------------------------------------------------------------------------------------------------------ --------- --------- --------- ------- ------- ------- -------- --------- --------- --------- ---------
  HR-CTV D~90~ \[%\]     5 ± 5                                                                                                  4 ± 3     4 ± 3     2 ± 2     2 ± 1   2 ± 2   2 ± 2   4 ± 4    5 ± 5     5 ± 5     6 ± 5     7 ± 5
  HR-CTV D~100~ \[%\]    8 ± 9                                                                                                  6 ± 5     5 ± 5     3 ± 2     3 ± 2   4 ± 3   3 ± 3   5 ± 5    6 ± 5     8 ± 6     9 ± 7     10 ± 7
  Rectum D~2cc~ \[%\]    19 ± 10                                                                                                14 ± 8    13 ± 8    11 ± 6    9 ± 6   5 ± 4   7 ± 4   15 ± 8   23 ± 11   33 ± 15   43 ± 22   65 ± 32
  Badder D~2cc~ \[%\]    10 ± 11                                                                                                7 ± 6     6 ± 5     5 ± 3     3 ± 3   3 ± 2   2 ± 1   3 ± 2    4 ± 2     5 ± 3     6 ± 4     8 ± 6
  Sigmoid D~2cc~ \[%\]   8 ± 7                                                                                                  7 ± 6     7 ± 7     6 ± 6     5 ± 5   6 ± 6   6 ± 4   8 ± 6    9 ± 6     12 ± 8    12 ± 10   16 ± 13
  Point A left \[%\]     1 ± 1                                                                                                  1 ± 1     2 ± 1     1 ± 2     1 ± 1   1 ± 1   1 ± 1   1 ± 1    1 ± 1     2 ± 2     1 ± 1     2 ± 1
  Point A right \[%\]    1 ± 1                                                                                                  1 ± 1     1 ± 1     1 ± 1     1 ± 1   1 ± 1   1 ± 1   1 ± 1    1 ± 1     2 ± 3     1 ± 1     1 ± 1
  ICRU rectum \[%\]      17 ± 9                                                                                                 12 ± 7    10 ± 7    8 ± 6     6 ± 5   4 ± 4   4 ± 3   9 ± 6    14 ± 7    20 ± 10   25 ± 13   41 ± 26
  ICRU bladder \[%\]     23 ± 23                                                                                                18 ± 16   14 ± 14   11 ± 10   8 ± 7   5 ± 5   3 ± 3   5 ± 3    7 ± 3     9 ± 4     11 ± 6    15 ± 8
                                                                                                                                                                                                                             
                         \< 5%                                                                                                  ≥ 5%      ≥ 10%     ≥ 15                                                                     

T&O -- tandem-and-ovoids, HR-CTV -- high risk clinical target volume, D~90~ (D~100~) -- minimum dose covering 90% (100%) of the volume, D~2cc~ -- dose of the 2cc of the highest dose, ICRU rectum (bladder) -- ICRU report \#38 defined rectal (bladder) point

The impact of T&O reconstruction-uncertainties was the most at ICRU bladder point doses ([Table 3](#T0003){ref-type="table"}). A 4.5 mm reconstruction-uncertainty caused 10% of dosimetric changes to ICRU bladder point doses. A 7.5 mm reconstruction-uncertainty in the caudal direction resulted in an average 10% change in ICRU rectal point doses. HR-CTV and point A doses presented relatively small changes, less than 10% per ± 7.5 mm T&O reconstruction uncertainties, for either point A plans or MRIG-CBT.

Discussion {#S0008}
==========

To the best of our knowledge, this is the first study of dosimetric impact due to T&O applicator displacements for both point A and MRIG-CBT plans. In addition, this is the first study presenting reconstruction uncertainty impact for both point A plans and MRIG-CBT plans. Regarding the impact of T&O displacements, MRIG-CBT plans demonstrate significantly larger dosimetric changes on sigmoid (*p* \< 0.0005), bladder (*p* \< 0.0001), HR-CTV (*p* \< 0.0036) than those of point A plans. It is mainly due to conformal isodose line target volumes and OARs. However, regardless of MRIG-CBT plans and point A plans, rectal D~2cc~ changed more than 10% for ± 3 mm T&O displacements. Our findings agree with those of Tanderup *et al*. \[[@CIT0008]\]. They found a mean change of 15% for the D~2cc~ values of the rectum and bladder due to 3 mm cranial-caudal displacement, when T&R or combined T&R + needles applicators were used for MRIG-CBT plans. Based upon our findings, a ± 1.5 mm T&O displacement allowed all dosimetric metrics to change less than 10%. For the purpose of this study, we simulated motion in both cranial and caudal directions, but in clinical practice, T&O displacement in the caudal direction typically occurs due to movement of the patient anatomy. As yet, no study presents intracavitary applicator displacements due to patient transfer for 3D image scans and their dosimetric impacts on dose-volumetric parameters using 3D images. Gerszten *et al*. reported an avg. 5 mm (range, 3 to 12 mm) displacement when using an immobilization device (see [Fig. 2](#F0002){ref-type="fig"} in \[[@CIT0009]\]) and 2D radiograph images. It is important to minimize intracavitary applicator displacement when transferring patients. One way to limit patient transfer for 3D image acquisition for image-guided HDR would be to install a CT scanner in the HDR BT room. However, CT provides limited information about macroscopic tumor volume for cervical cancer that MRI is able to provide \[[@CIT0005]\]. Another possible solution is to utilize one of the commercial immobilization systems such as those available from Zephyr patient transport system (DIACOR Inc., Salt Lake City, Utah, USA) using air-bearing techniques or MedTrak (MedTrak, LLC, Madison, Wisconsin, USA) that uses ceiling rails. Those systems are expected to reduce applicator displacement due to patient transfer. However, none of these support devices address applicator immobilization with respect to the patient. Our T&O support device was securely attached to the patient, allowing it to move as the patient does. In contrast to this, in some immobilization systems the immobilization device (see [Fig. 2](#F0002){ref-type="fig"} in \[[@CIT0009]\]) is secured to a transfer-board or a table, which can cause damage like uterine perforation due to even small patient movements. Applicator displacement can occur due to one or many reasons including anatomy changes due to insufficient anesthesia, suboptimal vaginal packing, and vibrations from the transfer table while in motion between rooms. Thus, the use of an applicator immobilizing device with respect to a patient is recommended even when a commercial immobilization system is in place. Even when using immobilization systems, applicator displacement must be carefully monitored when a patient is moved to different rooms for MRI or CT imaging. Studies for a robust immobilization system that limits motion, yet is still cost effective are expected to proliferate as 3D image-guided BT is more widely practiced in clinics.

Recently, planning uncertainties on 3D image guided BT have been widely explored in the literature. An sample of some of the reports include: the impact of uncertainties on planning and prescription \[[@CIT0025]\], inter- and intra-fractional anatomical variations \[[@CIT0026]\] and their dosimetric impact \[[@CIT0027]\], especially for pulse-dose-rate (PDR) BT, and critical structure movement between planning MRI and secondary MRI before HDR \[[@CIT0028]\] treatment. The overall D~2cc~ value of multiple BT fractions is obtained under the assumption that the approximate D~2cc~ location remains the same through multiple fractions. Jamema *et al*. \[[@CIT0029]\] evaluated inter-application variation of doses and spatial location of OAR D~2cc~, and found that the D~2cc~ locations were quite stable for bladder and rectum. However, significant topographical changes were reported for the sigmoid \[[@CIT0029]\]. For the bladder, the current simple DVH parameter addition was also validated as compared to the overall DVH through deformable image registration (DIR) by Andersen *et al*. \[[@CIT0030]\]. They found a current D~2cc~ addition for the bladder provides a good estimate, whereas D~0.1cc~ is less robust when compared to the values obtained using DIR. In relation to target volume delineation uncertainties, Petrič *et al*. found 0.76 (76% agreement) and 0.72 for HR-CTV for its simultaneous truth and performance level estimation, and expert consensus, respectively \[[@CIT0031]\]. HR-CTV was found to be more robust than gross target volume and intermediate risk CTV. The dosimetric impact of delineation uncertainty for HR-CTV and OARs were quantified by Hellebust *et al*. \[[@CIT0032]\]. They found that interobserver delineation variability caused ± 5 *Gy* ~α*/*β~ = 10 of equivalent dose in 2 Gy fraction (EQD2) for HR-CTV D~90~ and ±2-3 of EQD2 for OAR D~2cc~. Treatment planning technique variations among four T&O user institutions were compared for point A plans, T&O MRIG-CBT plans, and T&O + needles MRIG-CBT plans \[[@CIT0033]\]. Results indicated that adding interstitial needles to MRIG-CBT plans resulted in higher tumor coverage, but increased the variety in dose distributions between the institutions \[[@CIT0033]\]. The uncertainties of performing two HDR fractions within one applicator implant were reported by Lang *et al*. \[[@CIT0034]\]. They concluded that geometric differences between applicator, target, and OAR resulted in an overall dosimetric change (± 1.2 *Gy* ~α*/*β~ = 10 EQD2 of HR-CTV D~90~ and ± 0.7 -- 1.1 *Gy* ~α*/*β~ = 3 EQD2 for OAR D~2cc~) that could be of minor relevance in regard to clinical dose volume constraints.

To account for geometric uncertainties of applicator reconstruction or displacements, Tanderup *et al*. \[[@CIT0008], [@CIT0024]\] proposed a margin in the cranial direction only along a tandem (see [Fig. 1](#F0001){ref-type="fig"} in \[[@CIT0024]\]). Current 3D-imaging guidelines for GYN cancer \[[@CIT0002]--[@CIT0004], [@CIT0018]\] do not have margins to account for the uncertainties due to applicator displacements and/or an applicator reconstruction inaccuracy \[[@CIT0004], [@CIT0008]\]. As highlighted by Tanderup *et al*. \[[@CIT0024]\], the general planning target volume (PTV) concept should not be used to compensate for the uncertainties in 3D image guided brachytherapy (see [Fig. 2](#F0002){ref-type="fig"} in \[[@CIT0024]\]). They recommended not creating a general PTV margin, especially in the lateral and anterior-posterior directions as that could lead to a significant overall dose escalation: ∼8%/mm within the margin applied. Dose prescription or normalization to PTV was also strongly discouraged in the study \[[@CIT0024]\].

Conclusions {#S0009}
===========

Regarding the dosimetric impact of T&O displacement, rectal D~2cc~ values were observed as being most sensitive to change due to the T&O displacement among all dosimetric metrics regardless of point A (*p* \< 0.013) or MRIG-CBT plans (*p* \< 0.0277). To avoid greater than 10% changes, no more than ±1.5 mm T&O displacements were allowed for both point A and MRIG-CBT plans. The dosimetric impact of simulated T&O displacements on sigmoid (*p* \< 0.0005), bladder (*p* \< 0.0001), HR-CTV (*p* \< 0.0036), and point A (*p* \< 0.0015) were significantly larger in MRIG-CBT plans than point A plans. Regarding the dosimetric impact of T&O reconstruction-uncertainties, less than a ± 1.5 mm reconstruction-uncertainties was required in order to avoid a greater than 10% dosimetric change to point A plans.
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